Recombinant Proteins iso9001 ISO13485
搜索
>产品 > ADC药物靶点蛋白

ADC药物研发相关产品

背景
ADC(Antibody Drug Conjugate)是将单克隆抗体通过偶联臂与小分子药物共价偶联形成的复合物,通过将具有高度靶向性的抗体药与杀伤力强大的化疗药结合到一起,实现在肿瘤细胞内精准投放药物的同时避免化疗药对正常细胞的杀伤。随着ADC技术的发展,研究热度与日俱增。
ADC药物靶点蛋白及亲和力检测服务
ADC 的成功开发依赖于选择合适的靶点抗原,合适的药物靶点已经成为ADC研发企业关注的重点。
ACROBiosystems已针对多种热门靶点开发了不同种属、不同标签的产品,适用于免疫、抗体筛选、SPR、细胞活性检测等实验。ACROBiosystems致力于协助您的药物开发,并将研发人员实际的实验操作和参数整理成了相应的protocol免费提供,可以帮助您节省研发周期,后续更有过表达细胞株及Kit产品上线,敬请关注哦~
靶点蛋白产品列表

现可提供免费试用装,快来 点击申请 吧!

点击分子即可查看您感兴趣的产品详情哦

ACROBiosystems正在积极开发更多高质量ADC药物靶点分子。如果您有任何建议或定制要求,请随时与我们联系。联系我们

靶点蛋白产品特点
高纯度—MALS 验证

图1.The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.

图2.The purity of Human EGF R, His Tag(Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.

高亲和力-—SPR&BLI验证

图3.Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.

申请SPR Protocol 点击咨询SPR服务

图4.Loaded Herceptin (Trastuzumab) on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay.

申请BLI Protocol 点击咨询BLI服务

图5.Erbitux (Cetuximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay.

申请SPR Protocol 点击咨询SPR服务

图6.Loaded Erbitux (Cetuximab) on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay.

申请BLI Protocol 点击咨询BLI服务
亲和力检测服务
基于ACROBiosystems丰富的蛋白产品资源和活性分析经验,您只需提供样品,我们即可为您提供优质SPR&BLI亲和力检测服务,且免费提供实验所需的ADC靶点蛋白。
点击了解分子亲和力检测服务>>>

快速咨询

Genovis ADC Kits
抗体偶联药物是将具有高度靶向性的抗体与杀伤力强大的化疗药结合到一起而发挥作用的。功能齐全且有效的抗体-药物偶联物的设计和合成极具挑战性。
ACROBiosystems提供的专为ADC研发设计的偶联酶试剂盒-GlyCLICK ADC Kits,可以对所有IgG使用点击化学技术进行位点特异性和定量的缀合,产生稳定且完全标记的抗体偶联物。
  1. Generate a third-generation site-specific ADC using the GlyCLICK ADC products
  2. GlyCLICK ADC contents: enzymatic reagents for conjugation, hydrophilic and potent linker-payloads, optimized purification protocol.
产品列表

根据Payload作用机理的不同ACROBiosystems提供两种GlyCLICK ADC Kits

产品名称 货号 产品组分
GlyCLICK ADC kit PNU L1-T01-200 enzymatic reagents for conjugation, hydrophilic and potent linker-PUN, optimized purification protocolNew
GlyCLICK ADC kit MMAE L1-T02-200 enzymatic reagents for conjugation, hydrophilic and potent linker-MMAE, optimized purification protocolNew
产品特点
  1. >> 一盒搞定,配套提供Payloads
  2. >> 标记完全并且均一性强
  3. >> 二步法实现IgG独特位点的偶联
  4. >> 一个抗体偶联2个标记物
  5. >> 标记稳定可重复
验证数据
标记完全并且均一性强
GlyCILICK ADC kit可以高效完成抗体的标记
  1. The conjugation of trastuzumab and panitumumab was characterized using FabRICATOR digestion and LC-MS
  2. The data clearly shows specific modficiation of the Fc fragment with one drug per Fc, resulting in DAR 2.0 for the antibody. No unmodified antibody was detected.
两步特异酶切-高效释放毒素分子

GlyCILICK ADC kits偶联的ADC药物进入溶酶体后,可高效释放出毒素小分子,杀死靶细胞。

Unique Linker-payloads: PNU and MMAE
  1. The hydrophilic linkers contain a two-step cleavage ensure specific toxin release
  2. Optimized for use with the 2 mg GlyCLICK protocol
  3. MMAE blocks polymerization of tubulin
  4. PNU binds to DNA and inhibits transcription
  5. Collaboration with Glykos, Finland
细胞学活性验证

In vito cytotoxicity analysis of trastuzumab conjugated with the MMAE linker-payload using GlycLICK ADC kit MMAE. Her2+ SK-BR-3 cells were incubated with the ADC and cell viability measured with PrestoBlue after 5-6 days. Curves represent the average result from three replicates

In vito cytotoxicity analysis of trastuzumab conjugated with the PNU linker-payload using GlycLICK ADC kit PNU. Her2+ SK-BR-3 cells were incubated with the ADC and cell viability measured with PrestoBlue after 5-6 days. Curves represent the average result from three replicates

除上述ADC偶联试剂盒外,ACROBiosystems还提供同样高质量易操作的其他标记偶联试剂盒。

GlyCLICK 试剂盒产品列表
三步偶联法

消息提示

请输入您的联系方式,再点击提交!

确定